Sort   by:  
 Page size 
ProteomicsNovel Proteome Extraction Method Illustrate a Conserved Immunological Signature of MSI-H Colorectal Tumors
Utilizing the novel TOP clinical proteome extraction to better understand the immune phenotype of MSI-H CRC tumors
ORGANISM(S): Homo sapiens (Human) 
2020-07-10 | PXD017821 | Pride
Msi-h Mss Ffpe Crc 
GenomicsThe clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
PRJNA796219 | ENA
ProteomicsMachine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging
Background: Barrett’s esophagus (BE) is a precursor lesion of esophageal adenocarcinoma and may progress from non-dysplastic through low-grade dysplasia (LGD) to high-grade dysplasia (HGD) and cancer. Grading BE is of crucial prognostic value and is currently based on the subjective evaluation of bi...
ORGANISM(S): Homo sapiens (Human) 
2021-11-15 | PXD028949 | Pride
Deep learning Mass spectrometry imaging H&e staining Barrett’s esophagus Machine learning 
ClinicalRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
71370 | ecrin-mdr-crc
ClinicalPD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also recommended as an alternative choice for unresectable locally advanced colon cancer. Thus, this study will inves...
2332565 | ecrin-mdr-crc
ClinicalCadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer
This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.
64137 | ecrin-mdr-crc
TranscriptomicsThe clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
Endometrial cancer had a relatively high prevalence of MMR deficiency. MMR-D/MSI-H endometrial cancer patients are suggested to be potential beneficiaries of PD-1/PD-L1 inhibitor therapy. Here, we explored the prognostic value of MSI subtype in endometrial cancer and its correlation with immune envi...
ORGANISM(S): Homo sapiens 
2022-03-09 | GSE193430 | GEO
ClinicalToripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer
Colorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H cannot benefit from ...
2303741 | ecrin-mdr-crc
ClinicalTislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.
58728 | ecrin-mdr-crc
ClinicalAK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patie...
2352126 | ecrin-mdr-crc
Sort   by:  
 Page size